Edesa Licenses Japan Rights to Paridiprubart to Kyorin
On Nov. 09, 2026, Edesa Biotech and KYORIN Pharmaceutical entered an exclusive agreement covering development and commercialization of paridiprubart for acute respiratory distress syndrome in Japan. Edesa will receive an upfront payment and potential milestone payments, plus tiered double-digit royalties on Japanese net sales. Kyorin will fund Japan development, regulatory and commercial activities, while Edesa retains rights outside Japan.
Why it matters
The agreement gives Edesa near-term licensing proceeds and potential future royalties while shifting Japan development and commercialization funding to Kyorin. Edesa's CEO said the company views the deal as validation of its business model and a way to participate in the drug candidate's future success.
Key facts
- 1Edesa will receive an upfront payment of $12 million and may receive additional development, regulatory and sales-based milestones of up to approximately $134 million. saultstar.com
- 2Kyorin receives exclusive rights to develop and commercialize paridiprubart in Japan for ARDS and will fund related development, regulatory and commercialization activities. saultstar.com
- 3Edesa is eligible for tiered double-digit royalties on the product's net sales in Japan. saultstar.com
- 4Edesa retains all rights to paridiprubart outside Japan and will manufacture and supply the product to Kyorin. saultstar.com
- 5In a Phase 3 study, adjusted 28-day mortality was 39% with paridiprubart plus standard of care versus 52% with placebo, with p<0.001. saultstar.com
Summary written by AlphAI AI Desk from 8 of 8 sources. Not investment advice. Figures are as stated by the linked sources.